2017


To access this material please log in or register

Register Authorize
2017/№1

Peculiarities of using oral anticoagulants in the elderly

Vorobyeva N. M., Tkacheva O. N.
Federal State Budgetary Educational Institution of Higher Education, "Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation, "Russian Gerontology Clinical Research Center", 1st Leonova Str. 16

Keywords: new oral anticoagulants, warfarin, elderly, frailty

DOI: 10.18087/rhj.2017.1.2334

The review focuses on peculiarities of using oral anticoagulants, warfarin and new oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban), in the elderly in different clinical situations, including prevention of venous thromboembolic complications after orthopedic surgeries; prevention of cardioembolic stroke and systemic embolism in nonvalvular atrial fibrillation; and treatment of deep vein thrombosis and pulmonary embolism.
  1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J. 2013 Oct;34 (39):3028–34.
  2. Aronow WS. Approach to symptomatic coronary disease in the elderly: TIME to change? Lancet. 2001 Sep 22;358 (9286):945–6.
  3. Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging. 1999 Apr;14 (4):303–12.
  4. Hart RG, Pearce LA, Aguilar MI. Meta‑analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jul 19;146 (12):857–67.
  5. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005 Jun;127 (6):2049–56.
  6. Hylek EM, Evans‑Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007 May 29;115 (21):2689–96.
  7. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007 Aug 11;370 (9586):493–503.
  8. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double‑blind, non‑inferiority trial. Lancet. 2007 Sep 15;370 (9591):949–56.
  9. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al. Oral dabigatran etexilate versus subcutaneous enoxaparin for prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J Thromb Haemost. 2007 Nov;5 (11):2178–85.
  10. Turpie AG, Lassen MR , Eriksson BI, Gent M, Berkowitz SD, Misselwitz F et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies. Thromb Haemost. 2011 Mar;105 (3):444–53.
  11. Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR . Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‑2 and ADVANCE‑3 trials. J Bone Joint Surg Br. 2012 Feb;94 (2):257–64.
  12. Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Fukuzawa M et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J‑V. Thromb J. 2015 Aug 12;13:27.
  13. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361 (12):1139–51.
  14. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long‑term anticoagulant therapy (RE‑LY) trial. Circulation. 2011 May 31;123 (21):2363–72.
  15. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost. 2012 May;107 (5):838–47.
  16. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE‑LY (Randomized Evaluation of Long‑term Anticoagulation Therapy) trial analysis. Circulation. 2014 Mar 4;129 (9):961–70.
  17. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for non‑valvular atrial fibrillation. Circulation. 2015 Jan 13;131 (2):157–64.
  18. Patel MR , Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med. 2011 Sep 8;365 (10):883–91.
  19. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non‑valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011 Oct;32 (19):2387–94.
  20. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. New Eng J Med. 2011 Sep 15;365 (11):981–92.
  21. Halvorsen S, Atar D, Yang H, De Caterina R , Erol C, Garcia D et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014 Jul 21;35 (28):1864–72.
  22. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012 Nov;33 (22):2821–30.
  23. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R , Golitsyn S et al. Apixaban in patients with atrial fibrillation. New Engl J Med. 2011 Mar 3;364 (9):806–17.
  24. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369 (22):2093–104.
  25. Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta‑analysis of randomized trials. J Am Geriatr Soc. 2014 May;62 (5):857–64.
  26. Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‑stage renal disease on hemodialysis. J Clin Pharmacol. 2016 May;56 (5):628–36.
  27. Инструкция по применению препарата ELIQUIS (США). Регистр лекарственных средств России. – ООО «РЛС‑Патент». 2016 [Instrukcziya po primeneniyu preparata ELIQUIS (SShA). Registr lekarstvenny`x sredstv Rossii. – OOO «RLS‑Patent». 2016].
  28. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37 (38):2893–962.
  29. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10;361 (24):2342–52.
  30. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129 (7):764–72.
  31. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010 Jun;64 (7):956–67.
  32. Bauersachs R , Berkowitz SD, Brenner B, Buller HR , Decousus H, Gallus AS et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363 (26):2499–510.
  33. Buller HR , Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366 (14):1287–97.
  34. Agnelli G, Buller HR , Cohen A, Curto M, Gallus AS, Johnson M et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369 (9):799–808.
  35. Buller HR , Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369 (15):1406–15.
  36. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‑Based Clinical Practice Guidelines. Chest. 2012 Feb;141 (2 Suppl): e419S‑94S.
  37. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et al. Antithrombotic therapy for VTE disease: CHEST Guideline and expert panel report. Chest. 2016 Feb;149 (2):315–52.
  38. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004 Mar;59 (3):255–63.
  39. Bales CW, Ritchie CS. Sarcopenia, weight loss, and nutritional frailty in the elderly. Annu Rev Nutr. 2002;22:309–23.
  40. Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing. 2009 Mar;38 (2):156–62
Vorobyeva N.M., Tkacheva O.N. Peculiarities of using oral anticoagulants in the elderly. Russian Heart Journal. 2017;16 (1):10–19.

To access this material please log in or register

Register Authorize
Ru En